PGR and breast cancer: As a typical RWS, our study focuses on confirmed estrogen receptor (ER)+HER2− BC with locally recurrent or metastatic disease; specifically, 87.4% of our patients were ER+ progesterone receptor (PR)+, while 12.6% were ER+PR–.